Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

NCT00578617 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-01-04

Study results available
· View outcomes & findings →

Summary

The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.

Conditions

Interventions

DRUG

Rate Control

Metoprolol 50-100mg

DEVICE

Ablation Therapy

DRUG

Rate Control

Atenolol 50-100mg,

DRUG

Rate control

Propranolol 40-80mg

DRUG

Rate control

Acebutolol 200mg

DRUG

Rate control

Carvedilol 6.25mg

DRUG

Rate Control

Diltiazem 180-240mg

DRUG

Rate Control

Verapamil 180-240mg

DRUG

Rate Control

Digoxin 0.125mg

DRUG

Rhythm Control

Propafenone 450mg

DRUG

Rhythm control

Flecainide 200mg

DRUG

Rhythm control

Sotalol 240mg

DRUG

Rhythm control

Dofetilide 500mcg

DRUG

Rhythm control

Amiodarone 200mg

DRUG

Rhythm control

Quinidine 600-900mg

Sponsors & Collaborators

  • Duke Clinical Research Institute

    collaborator OTHER
  • Abbott Medical Devices

    collaborator INDUSTRY
  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Douglas L. Packer, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-02-28
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00578617 on ClinicalTrials.gov